In clinical studies, intravenous Monjuvi combined with oral lenalidomide led to a partial or complete response (overall response rate) in 55% of patients (39 of 71) with advanced diffuse large B-cell lymphoma (DLBCL) who received treatment for up to 12 cycles. The median duration of response was 21.7 months.